Customer: Gatt Technology from Nijmegen, the Netherlands
Author: Johan Bender
GATT Technologies BV entered a research cooperation with Vosfox Medical regarding GATT’s implantable hemostat GATT-Patch in January 2018. This project needed quite some flexibility and commitment from Vosfox as timelines were crucial and output needed to be at the highest quality level. All parameters were met by Vosfox, and exceeding. GATT-Patch samples created were tested in an in-vivo study and performed very well regarding hemostasis and adhesion.